Sonodynamic Therapy Based on Combined Use of Low Dose Administration of Epirubicin-Incorporating Drug Delivery System and Focused Ultrasound

Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around ne...

Full description

Saved in:
Bibliographic Details
Published inUltrasound in medicine & biology Vol. 43; no. 10; pp. 2295 - 2301
Main Authors Maeda, Masanori, Muragaki, Yoshihiro, Okamoto, Jun, Yoshizawa, Shin, Abe, Nobutaka, Nakamoto, Hidekazu, Ishii, Hiroshi, Kawabata, Kenichi, Umemura, Shinichiro, Nishiyama, Nobuhiro, Kataoka, Kazunori, Iseki, Hiroshi
Format Journal Article
LanguageEnglish
Published England Elsevier Inc 01.10.2017
Subjects
Animals
Antibiotics, Antineoplastic - administration & dosage
Colon cancer
Combined Modality Therapy - methods
Dose-Response Relationship, Drug
Drug delivery system (DDS)
Drug Delivery Systems - methods
Epirubicin
Epirubicin - administration & dosage
High intensity focused ultrasound (HIFU)
In vivo
Mice
Micellar
Models, Animal
Pancreatic cancer
Sonodynamic therapy (SDT)
Ultrasonic Therapy - methods
Sonodynamic therapy (SDT)
Colon cancer
Micellar
In vivo
Pancreatic cancer
High intensity focused ultrasound (HIFU)
Epirubicin
Drug delivery system (DDS)
Online AccessGet full text

Cover

More Information
Summary:Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around neoplastic cells. Anthracycline drugs, including epirubicin (EPI), have been well known as effective sonosensitizers after interaction with focused ultrasound. Recently a new anticancer drug delivery system (DDS), NC-6300, has been developed that comprises EPI through an acid–labile hydrazone bond. In previous in vivo studies, NC-6300 showed basic drug safety and an excellent concentration property of EPI, and recently has been tested in clinical trials. For realizing minimally invasive cancer treatment, the present study demonstrated the effectiveness and feasibility of DDS-based SDT, which combined a small dose of NC-6300 and low energy of HIFU in mouse models of colon cancer and pancreatic cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0301-5629
1879-291X
DOI:10.1016/j.ultrasmedbio.2017.06.003